Abstract | BACKGROUND: OBJECTIVE: METHODS: The recent literature is reviewed. RESULTS: Recent reports suggest that certain ichthyoses (particularly the hyperproliferative variants) and keratodermas may respond to topical calcipotriene ointment. The activity of calcipotriene relates to a dose-dependent decrease in proliferation and an increase in terminal differentiation of keratinocytes. CONCLUSION: Patients with other disorders characterized by epidermal hyperproliferation may also be candidates for treatment. The use of calcipotriene in treating congenital hyperproliferative disorders is limited by the theoretical risk of hypercalcemia from absorption of the drug after application to extensive areas of skin.
|
Authors | B H Thiers |
Journal | Journal of the American Academy of Dermatology
(J Am Acad Dermatol)
Vol. 37
Issue 3 Pt 2
Pg. S69-71
(Sep 1997)
ISSN: 0190-9622 [Print] United States |
PMID | 9344189
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
|
Chemical References |
- Dermatologic Agents
- Ointments
- calcipotriene
- Calcitriol
|
Topics |
- Administration, Topical
- Arthritis, Reactive
(drug therapy)
- Calcitriol
(administration & dosage, adverse effects, analogs & derivatives, pharmacokinetics, therapeutic use)
- Cell Differentiation
(drug effects)
- Cell Division
(drug effects)
- Dermatologic Agents
(administration & dosage, adverse effects, pharmacokinetics, therapeutic use)
- Dose-Response Relationship, Drug
- Foot Dermatoses
(drug therapy)
- Hand Dermatoses
(drug therapy)
- Humans
- Hypercalcemia
(chemically induced)
- Ichthyosis
(drug therapy)
- Keratinocytes
(drug effects)
- Keratosis
(drug therapy)
- Nail Diseases
(drug therapy)
- Ointments
- Pityriasis Rubra Pilaris
(drug therapy)
- Psoriasis
(drug therapy)
- Skin Absorption
- Skin Diseases
(congenital, drug therapy)
|